LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 113

Search options

  1. Article ; Online: Calcium pyrophosphate deposition disease moves into the spotlight.

    Dalbeth, Nicola / Tedeschi, Sara K

    The Lancet. Rheumatology

    2023  Volume 5, Issue 9, Page(s) e497–e499

    MeSH term(s) Humans ; Chondrocalcinosis/diagnosis
    Language English
    Publishing date 2023-08-08
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(23)00188-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment.

    Sparks, Jeffrey A / Tedeschi, Sara K

    The Lancet. Respiratory medicine

    2022  Volume 10, Issue 9, Page(s) 813–815

    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Immunogenicity, Vaccine ; Immunosuppressive Agents ; Methotrexate/therapeutic use
    Chemical Substances COVID-19 Vaccines ; Immunosuppressive Agents ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(22)00224-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Editorial: Updates in crystal deposition diseases.

    Tedeschi, Sara K

    Current opinion in rheumatology

    2019  Volume 31, Issue 2, Page(s) 132–133

    Language English
    Publishing date 2019-01-29
    Publishing country United States
    Document type Introductory Journal Article ; Editorial
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000581
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Issues in CPPD Nomenclature and Classification.

    Tedeschi, Sara K

    Current rheumatology reports

    2019  Volume 21, Issue 9, Page(s) 49

    Abstract: Purpose of review: This paper covers confusion and challenges in the nomenclature of calcium pyrophosphate deposition disease. Clinicians, investigators, and patients are faced with a variety of terms that are used to describe CPPD and its phenotypes, ... ...

    Abstract Purpose of review: This paper covers confusion and challenges in the nomenclature of calcium pyrophosphate deposition disease. Clinicians, investigators, and patients are faced with a variety of terms that are used to describe CPPD and its phenotypes, and clarity is greatly needed to help advance research and patient care. Motivation for the upcoming development of CPPD classification criteria is reviewed.
    Recent findings: EULAR proposed recommended terminology for CPPD in 2011. International Classification of Diseases (ICD-9 and ICD-10) billing codes identify definite or probable CPPD with variable accuracy depending on the clinical setting and comparator group. READ diagnostic codes have been employed to identify pseudogout in UK datasets but their accuracy has not been evaluated. CPPD classification criteria will provide a system for identifying a relatively homogenous group of patients to be included in clinical studies, enabling comparison of outcomes across studies. CPPD nomenclature remains challenging for clinicians, investigators, and patients. A lay-friendly definition of CPPD, using easily accessible terminology, would be welcome. CPPD classification criteria are a necessary step in moving forward CPPD clinical research and may involve a range of clinical, laboratory, and imaging modalities.
    MeSH term(s) Calcium Pyrophosphate ; Chondrocalcinosis/classification ; Chondrocalcinosis/diagnostic imaging ; Chondrocalcinosis/pathology ; Humans ; International Classification of Diseases ; Terminology as Topic
    Chemical Substances Calcium Pyrophosphate (X69NU20D19)
    Language English
    Publishing date 2019-07-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057357-1
    ISSN 1534-6307 ; 1523-3774
    ISSN (online) 1534-6307
    ISSN 1523-3774
    DOI 10.1007/s11926-019-0847-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Review: Outcome measures in calcium pyrophosphate deposition.

    Cai, Ken / Tedeschi, Sara K

    Best practice & research. Clinical rheumatology

    2021  Volume 35, Issue 4, Page(s) 101724

    Abstract: This review highlights outcomes for patients with calcium pyrophosphate deposition (CPPD) reported in prior studies and underscores challenges to assessing outcomes of this condition. Prior clinical studies of interventions for CPPD focused on joint ... ...

    Abstract This review highlights outcomes for patients with calcium pyrophosphate deposition (CPPD) reported in prior studies and underscores challenges to assessing outcomes of this condition. Prior clinical studies of interventions for CPPD focused on joint damage and calcification on imaging tests, joint pain, swelling, and inflammatory biomarkers. Qualitative interviews with patients with CPPD and healthcare providers additionally identified flares, overall function, and use of analgesic medications as important outcomes. Imaging evidence of joint damage and calcification is likely to be outcomes in future clinical studies of CPPD, though reliability and sensitivity to change in CPPD require further testing for several imaging modalities. Challenges to outcome measurement in CPPD include questions of attribution of signs and symptoms to CPPD versus co-existing forms of arthritis, lack of therapies to prevent or dissolve calcium pyrophosphate crystal deposition, absence of validated patient- or physician-reported CPPD outcome measures, and scarcity of large cohorts in which to study outcomes of different clinical presentations of CPPD.
    MeSH term(s) Calcium Pyrophosphate ; Chondrocalcinosis/diagnostic imaging ; Humans ; Outcome Assessment, Health Care ; Reproducibility of Results
    Chemical Substances Calcium Pyrophosphate (X69NU20D19)
    Language English
    Publishing date 2021-11-17
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2052323-3
    ISSN 1532-1770 ; 1521-6942
    ISSN (online) 1532-1770
    ISSN 1521-6942
    DOI 10.1016/j.berh.2021.101724
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Patient-Reported Outcomes in Calcium Pyrophosphate Deposition Disease Compared to Gout and Osteoarthritis.

    Whelan, Mary Grace / Hayashi, Keigo / Altwies, Hallie / Tedeschi, Sara K

    The Journal of rheumatology

    2023  Volume 50, Issue 8, Page(s) 1058–1062

    Abstract: Objective: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to that of gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind research in these other forms of arthritis. We compared validated patient-reported ... ...

    Abstract Objective: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to that of gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind research in these other forms of arthritis. We compared validated patient-reported outcome measures in patients with CPPD vs gout and OA.
    Methods: Patients with CPPD were recruited from Brigham and Women's Hospital from 2018 to 2022. Presence of CPPD manifestations (acute calcium pyrophosphate [CPP] crystal arthritis, chronic CPP inflammatory arthritis, and/or OA with CPPD) was confirmed by medical record review. Baseline surveys included the Gout Assessment Questionnaire version 2.0, modified to ask about "pseudogout" rather than "gout"; Routine Assessment of Patient Index Data 3 (RAPID-3); and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We compared responses in patients with CPPD against published gout and OA cohort studies.
    Results: Among 47 patients with CPPD, the mean age was 71.9 years and 51% were female. Sixty-eight percent had at least 1 episode of acute CPP crystal arthritis, 40% had chronic CPP inflammatory arthritis, and 62% had OA with CPPD. Pain visual analog scale scores during a flare were similar in CPPD (mean 6.8 [SD 1.9]) and gout (mean 6.7 [SD 2.6];
    Conclusion: Patients with CPPD may experience pain comparable to that in gout and OA and reported substantial unmet treatment needs.
    MeSH term(s) Humans ; Female ; Aged ; Male ; Chondrocalcinosis ; Calcium Pyrophosphate ; Gout/complications ; Gout/drug therapy ; Osteoarthritis/complications ; Calcinosis ; Patient Reported Outcome Measures
    Chemical Substances Calcium Pyrophosphate (X69NU20D19) ; diphosphoric acid (4E862E7GRQ)
    Language English
    Publishing date 2023-04-15
    Publishing country Canada
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    DOI 10.3899/jrheum.2023-0031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Response letter to the editor.

    Tedeschi, Sara K / Solomon, Daniel H / Rao, Deepak A / Jonsson, A Helena / Wesemann, Duane R

    Seminars in arthritis and rheumatism

    2023  Volume 61, Page(s) 152223

    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Letter
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2023.152223
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Picturing Giant Cell Arteritis: Projecting Into the Future.

    Tedeschi, Sara K / Aghayev, Ayaz

    Arthritis & rheumatology (Hoboken, N.J.)

    2019  Volume 71, Issue 8, Page(s) 1211–1214

    MeSH term(s) Cross-Sectional Studies ; Double-Blind Method ; Giant Cell Arteritis ; Head ; Humans ; Prospective Studies
    Language English
    Publishing date 2019-06-21
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.40871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Fractures in Patients With Acute Calcium Pyrophosphate Crystal Arthritis Versus Matched Comparators in a Large Cohort Study.

    Tedeschi, Sara K / Hayashi, Keigo / Rosenthal, Ann / Gill, Muneet / Marrugo, Javier / Fukui, Sho / Gravallese, Ellen / Solomon, Daniel H

    Arthritis & rheumatology (Hoboken, N.J.)

    2024  

    Abstract: Objective: Calcium pyrophosphate deposition (CPPD) disease was associated with osteopenia in two cross-sectional studies. We compared fracture risks in patients with acute calcium pyrophosphate (CPP) crystal arthritis versus matched comparators.: ... ...

    Abstract Objective: Calcium pyrophosphate deposition (CPPD) disease was associated with osteopenia in two cross-sectional studies. We compared fracture risks in patients with acute calcium pyrophosphate (CPP) crystal arthritis versus matched comparators.
    Methods: We performed a longitudinal cohort study using electronic health record data from a single large academic health system, with data from 1991 to 2023. Patients with one or more episodes of acute CPP crystal arthritis were matched to comparators on the index date (first documentation of "pseudogout" or synovial fluid CPP crystals or matched encounter) and first encounter in the health system. The primary outcome was first fracture at the humerus, wrist, hip, or pelvis. We excluded patients with fracture before the index date. Covariates included demographics, body mass index, smoking, comorbidities, health care use, glucocorticoids, and osteoporosis treatments. We estimated incidence rates and adjusted hazard ratios for fracture. Sensitivity analyses excluded patients prescribed glucocorticoids, patients prescribed osteoporosis treatments, or patients with rheumatoid arthritis and additionally adjusted for chronic kidney disease.
    Results: We identified 1,148 patients with acute CPP crystal arthritis matched to 3,730 comparators, with a mean age of 73 years. Glucocorticoids and osteoporosis treatments were more frequent in the acute CPP crystal arthritis cohort. Fracture incidence rates were twice as high in the acute CPP crystal arthritis cohort (11.7 per 1,000 person-years) versus comparators (5.5 per 1,000 person-years). After multivariable adjustment, fracture relative risk was twice as high in the acute CPP crystal arthritis cohort (hazard ratio 1.8 [95% confidence interval 1.3-2.3]); results were similar in sensitivity analyses.
    Conclusion: In this first published study of fractures and CPPD, fracture risk was nearly doubled in patients with acute CPP crystal arthritis.
    Language English
    Publishing date 2024-01-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis.

    Tedeschi, Sara K / Huang, Weixing / Yoshida, Kazuki / Solomon, Daniel H

    Annals of the rheumatic diseases

    2022  

    Abstract: Objectives: Calcium pyrophosphate deposition (CPPD) disease, broadly defined, has been associated with increased risk of cardiovascular (CV) events. We investigated risk of CV events in patients with acute CPP crystal arthritis, the acute manifestation ... ...

    Abstract Objectives: Calcium pyrophosphate deposition (CPPD) disease, broadly defined, has been associated with increased risk of cardiovascular (CV) events. We investigated risk of CV events in patients with acute CPP crystal arthritis, the acute manifestation of CPPD.
    Methods: Cohort study using Mass General Brigham electronic health record (EHR) data, 1991-2017. Patients with acute CPP crystal arthritis were identified using a published machine learning algorithm with positive predictive value 81%. Comparators were matched on year of EHR entry and index date of patients with acute CPP crystal arthritis (first positive synovial fluid CPP result or mention of 'pseudogout', or matched encounter). Major adverse cardiovascular event (MACE) was a composite of non-fatal CV event (myocardial infarction, acute coronary syndrome, coronary revascularisation, stroke) and death. We estimated incidence rates (IRs) and adjusted hazard ratios for MACE, non-fatal CV event and death, allowing for differential estimates during years 0-2 and 2-10. Sensitivity analyses included: (1) patients with acute CPP crystal arthritis diagnosed during outpatient visits, (2) patients with linked Medicare data, 2007-2016 and (3)patients matched on number of CV risk factors.
    Results: We matched 1200 acute CPP crystal arthritis patients to 3810 comparators. IR for MACE in years 0-2 was 91/1000 person-years (p-y) in acute CPP crystal arthritis and 59/1000 p-y in comparators. In years 2-10, IR for MACE was 58/1000 p-y in acute CPP crystal arthritis and 53/1000 p-y in comparators. Acute CPP crystal arthritis was significantly associated with increased risk for MACE in years 0-2 (HR 1.32, 95% CI 1.01 to 1.73) and non-fatal CV event in years 0-2 (HR 1.92, 95% CI 1.12 to 3.28) and years 2-10 (HR 2.18, 95% CI 1.27 to 3.75), but not death. Results of sensitivity analyses were similar to the primary analysis; in the outpatient-only analysis, risk of non-fatal CVE was significantly elevated in years 2-10 but not in years 0-2.
    Conclusions: Acute CPP crystal arthritis was significantly associated with elevated short and long-term risk for non-fatal CV event.
    Language English
    Publishing date 2022-05-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2022-222387
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top